RCKT, US77313F1066

Rocket Pharmaceuticals stock fell 7.63 percent to USD 2.18, 0.46 percent above yearly low

Published on 10/17/2026 at 19:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Rocket Pharmaceuticals stock stood at USD 2.18 on October 16, 2026, down 7.63 percent. Leerink Partners cut target to USD 4.00 from USD 7.00 on October 7.

Price pressure and analyst targets

  • Rocket Pharmaceuticals stock fell 7.63 percent on Nasdaq on October 16, 2026.
  • Leerink Partners cut its target from USD 7.00 to USD 4.00 on October 7.
  • Rocket Pharmaceuticals stock stood at USD 2.18 on Nasdaq on October 16, 2026 at 4:00 p.m. EDT, down 7.63 percent versus the prior close of USD 2.36.
  • The company had a market capitalization of USD 239.3 million and a trailing P/E ratio of -12.82.
RCKT, US77313F1066, Illustration mit AI erstellt.

Rocket Pharmaceuticals stock fell 7.63 percent on Nasdaq on October 16, 2026, finishing the completed US session at USD 2.18, just USD 0.01 above its 52-week low of USD 2.17. The move places the rare-disease biotechnology company under renewed scrutiny as analysts reassess its clinical pipeline and valuation.

Analyst target falls to USD 4.00

MarketBeat reported on October 7, 2026 that Leerink Partners cut its target for Rocket Pharmaceuticals from USD 7.00 to USD 4.00 while maintaining a market perform rating. The new target stood 83.49 percent above the USD 2.18 stock price, using the same Nasdaq quotation currency.

Price position after the drop

The October 16, 2026 Nasdaq session ranged from USD 2.17 to USD 2.33, while volume reached 1,966,675 shares against an average volume of 1,766,985. The stock therefore traded at the bottom of its 52-week range, which extends to USD 5.45 at the upper end.

Rocket Pharmaceuticals develops gene therapies for rare and severe diseases, using ex vivo and in vivo approaches. Its corporate profile describes three ex vivo lentiviral programs and an in vivo adeno-associated virus program for Danon disease; the company presents the same focus on its investor site at Rocket Pharmaceuticals.

Valuation remains in focus

Rocket Pharmaceuticals had a market capitalization of USD 239.3 million and a trailing P/E ratio of -12.82 on October 16, 2026. The stock paid no trailing dividend, while the 12-month analyst consensus cited by MarketBeat was USD 7.66 from 12 analysts on October 7, 2026.

Comparison with peers

Sarepta Therapeutics (Nasdaq, USD): minus 3.88 percent, P/E -5.90, market capitalization USD 1.8 billion.
Ultragenyx Pharmaceutical (Nasdaq, USD): minus 4.15 percent, P/E -2.49, market capitalization USD 1.4 billion.
Rocket Pharmaceuticals (Nasdaq, USD): minus 7.63 percent, P/E -12.82, market capitalization USD 239.3 million.

Nasdaq closing level sets the frame

Rocket Pharmaceuticals last stood at USD 2.18 on Nasdaq on October 16, 2026 at 4:00 p.m. EDT, down 7.63 percent versus the prior close of USD 2.36. Its USD 2.17 52-week low is the nearest established chart marker.

Market context: Market report S&P 500.

Rocket Pharmaceuticals at a glance

  • Company: Rocket Pharmaceuticals, Inc.
  • ISIN: US77313F1066
  • Ticker: RCKT
  • Primary exchange: Nasdaq Global Market
  • Price Nasdaq as of October 16, 2026, 4:00 p.m. EDT: USD 2.18
  • Change versus prior close: minus 7.63 percent
  • Prior close: USD 2.36
  • Market capitalization: USD 239.3 million as of October 16, 2026
  • 52-week range: USD 2.17-5.45 as of October 16, 2026
  • Sector / Industry: Healthcare / Biotechnology
  • Trailing P/E ratio: -12.82 as of October 16, 2026

Market context: Market report S&P 500.

More news and analyses on Rocket Pharmaceuticals stock

Disclaimer...
en | US77313F1066 | RCKT | boerse | 70349328 | bgmi